Science & Technology
Meganuclease-mediated gene editing for durable control of HSV-2 infection
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AI186683-01
Award Ceiling
$607K
Award Floor
$607K
Close Date
Jul 31, 2026
138 days leftTotal Funding
$607K
Expected Awards
1
Posted Date
Aug 5, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AI186683-01
Description
STTR Phase Phase I award: "Meganuclease-mediated gene editing for durable control of HSV-2 infection" awarded to Caladan Therapeutics, Inc. in VESTAVIA HILLS, Alabama. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $607,462. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.